Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Piperazine fibrinogen antagonists from Thomae

Aug. 9, 1996

RO-11 demonstrates efficacy in phase III as DVT prevention agent

Aug. 9, 1996

Thrombin inhibitors inhelabo's pipeline

Aug. 9, 1996

RPR's enoxaparin reduces risk of DVT following hip replacement

Aug. 9, 1996

Hemaseel HMN phase I results announced

Aug. 9, 1996

Antithrombotic/antiallergic TxA2 synthase inhibitors from Terumo

July 26, 1996

Pharmacia & Upjohn introduces new dosage strength for Fragmin

July 26, 1996

D-HG: DIC/thrombosis treatment

July 26, 1996

BASF reports thrombin inhibitors

July 26, 1996

The Immune Response Corporation and Bayer to codevelop hemophilia A gene therapy

July 19, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...